Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates

Harrow Health (HROW) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 80%. A quarter ago, it was expected that this pharmaceutical and drug compounding company would post a loss of $0.50 per share when it actually produced a loss of $0.50, delivering no surprise.
Over the last f…

Click here to view the original article.